HF
AIM

HRT Financial’s AIM ImmunoTech AIM Stock Holding History

HRT Financial’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,032
Closed -$15K – 5697
2026
Q1 		$15K Buy
+26,032
New +$26.4K ﹤0.01% 3598
2025
Q1 		– Sell
-317
Closed -$6K – 3633
2024
Q4 		$6K Sell
317
-31
-9% -$722 ﹤0.01% 2322
2024
Q3 		$9K Buy
+348
New +$11.6K ﹤0.01% 2236
2023
Q4 		– Sell
-108
Closed -$4K – 3395
2023
Q3 		$4K Buy
+108
New +$6.66K ﹤0.01% 2212
2021
Q1 		– Sell
-117
Closed -$20K – 3441
2020
Q4 		$20K Buy
+117
New +$23.4K ﹤0.01% 1744
2020
Q2 		– Sell
-100
Closed -$25K – 1877
2020
Q1 		$25K Buy
+100
New +$15.7K ﹤0.01% 670

Other funds holding AIM

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

HRT Financial's AIM Position: Q2 2026 in Review

HRT Financial sold out of AIM ImmunoTech (AIM) in Q2 2026, closing a stake of 26,032 shares — an estimated $15K sold.

HRT Financial first reported a position in AIM in Q1 2020 and held it in 6 quarters. The position peaked at $25K in Q1 2020. 18 funds tracked by Wall St. Rank hold AIM as of Q2 2026.

  • HRT Financial reported no remaining AIM ImmunoTech position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 26,032 AIM ImmunoTech shares in Q2 2026, an estimated $15K.
  • HRT Financial first reported a position in AIM ImmunoTech in Q1 2020 and held it in 6 quarters.
  • HRT Financial's AIM ImmunoTech position peaked at $25K in Q1 2020.
  • 18 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.